News
Roche pauses Sarepta gene therapy shipments outside U.S.
Digest more
European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...
1hon MSN
Wall Street ended higher on Friday, capping off a strong week that saw both the Nasdaq Composite and S&P 500 finish the week ...
The FDA is investigating the death last month of an eight-year-old boy in Brazil who had received Sarepta Therapeutics’ Elevidys® (delandistrogene moxeparvovec-rokl)—though the company and its ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
InvestorsHub on MSN2d
Sarepta shares drop after EU regulators reject Elevidys gene therapyShares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European ...
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Sarepta Therapeutics, Inc. also has a pipeline against Limb-Girdle muscular dystrophy, which causes weakness and wasting of the muscles starting around hips and shoulders and progressing to ...
Cambridge-based Sarepta Therapeutics to charge $3.2M for new Duchenne muscular dystrophy treatment. First gene therapy for deadly muscle-wasting disease approved Thursday by FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback